JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
01/12/22 - 18:30
2023 Annual Calendar of Corporate Events (288 KB)
09/11/22 - 7:04
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
07/11/22 - 7:12
DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
27/10/22 - 13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
05/10/22 - 6:37
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
14/09/22 - 0:29
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
03/08/22 - 12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
14/07/22 - 20:00
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
07/06/22 - 18:06
Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
20/05/22 - 7:08
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
09/05/22 - 7:02
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
06/05/22 - 17:33
Update 2022 Annual Calendar of Corporate Events (285.68 KB)
06/05/22 - 16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
02/05/22 - 12:55
Publication of the summary report of the votes cast (280.95 KB)
29/04/22 - 16:26
Shareholders' meeting 2022 (166.12 KB)
22/04/22 - 12:37
New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
13/04/22 - 16:43
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
08/04/22 - 19:13
Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
08/04/22 - 9:53
Update annual calendar of corporate events 2022 (288.09 KB)
05/04/22 - 9:51
Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
04/04/22 - 18:12
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
16/03/22 - 17:39
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
08/03/22 - 7:13
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
13/01/22 - 7:24
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
23/12/11 - 1:00
Financial instruments to employees (57.22 KB)
19/12/11 - 1:00
Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)
19/11/11 - 1:00
Buy-back plan (35.47 KB)
18/11/11 - 1:00
Financial instruments to employees (56.82 KB)
11/11/11 - 1:00
The BoD approves Q3'11 results (334.35 KB)
28/10/11 - 2:00
Buy-back plan (103.99 KB)
25/10/11 - 2:00
Buy-back plan (104.72 KB)
18/10/11 - 2:00
Buy-back plan (136.18 KB)
17/10/11 - 2:00
2011-2015 Business Plan: a new business wave (195.1 KB)
10/10/11 - 2:00
New Chief Financial Officer (196.26 KB)
06/10/11 - 2:00
Cardinal Health: agreement extended to 2014 (192.57 KB)
04/10/11 - 2:00
Buy-back plan (204.92 KB)
01/09/11 - 2:00
Resignation of Chief Financial Officer (177.77 KB)
31/08/11 - 2:00
2011 Financial calendar update (176.4 KB)
03/08/11 - 2:00
The BoD approves H1'11 results (324.48 KB)
11/07/11 - 2:00
Voluntarily removal from the STAR segment (194.93 KB)
13/05/11 - 2:00
The BoD approves Q1'11 results (307.28 KB)
11/05/11 - 2:00
DiaSorin and Labcorp extend strategic business relationship (100.01 KB)
06/05/11 - 2:00
Agreement with Precision System Science Co., LTD (171.54 KB)
28/04/11 - 2:00
The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)
16/03/11 - 1:00
The BoD approves FY'10 results (368.28 KB)
16/03/11 - 1:00
Dividend information amendment (159.83 KB)
28/02/11 - 1:00
2011 Financial calendar update (179.92 KB)
19/02/11 - 1:00
Notice of change in share capital (5.28 KB)
18/02/11 - 1:00
Buy-back plan (134.06 KB)
17/02/11 - 1:00
Financial instruments to employees (56.37 KB)
16/02/11 - 1:00
Buy-back plan (105.2 KB)
15/02/11 - 1:00
Buy-back plan (91.38 KB)
14/02/11 - 1:00
The BoD approves Q4'10 results (161 KB)
31/01/11 - 1:00
Buy-back plan (105.05 KB)
29/01/11 - 1:00
Buy-back plan (105.2 KB)
28/01/11 - 1:00
Buy-back plan (105.04 KB)
27/01/11 - 1:00
Buy-back plan (105.04 KB)
26/01/11 - 1:00
FDA approves the LIAISON XL (194.2 KB)
25/01/11 - 1:00
Buy-back plan (105.22 KB)
24/01/11 - 1:00
Buy-back plan (104.72 KB)
21/01/11 - 1:00
Buy-back plan (105.05 KB)
20/01/11 - 1:00
Buy-back plan (91.39 KB)
19/01/11 - 1:00
Buy-back plan (105.31 KB)
18/01/11 - 1:00
Buy-back plan (35.47 KB)
17/01/11 - 1:00
Buy-back plan (134.01 KB)
17/01/11 - 1:00
The Sonic Healthcare Group chooses DiaSorin (181.71 KB)
16/01/11 - 1:00